Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 529

1.

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, Dombret H.

Blood. 2002 May 15;99(10):3517-23.

2.

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Dombret H; French Acute Myeloid Leukemia Intergroup.; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques.; Leucémies Aiguës Myéoblastiques de l'Enfant.; Acute Leukemia French Association.; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups..

Blood. 2003 Jul 15;102(2):462-9. Review.

3.

Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Tavernier E, Le QH, Elhamri M, Thomas X.

Leuk Res. 2003 Mar;27(3):205-14.

PMID:
12537972
4.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A.

Blood. 1998 Oct 1;92(7):2322-33.

5.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90.

PMID:
12928754
6.
7.

Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22).

Chen CC, Gau JP, Yu YB, Lu CH, Lee KD, You JY.

Adv Ther. 2007 Jul-Aug;24(4):907-20.

PMID:
17901040
8.

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology..

Haematologica. 2002 Feb;87(2):154-66.

9.

Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.

Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, Pigneux A, Quesnel B, Witz F, Thépot S, Ugo V, Terre C, Recher C, Tavernier E, Hunault M, Esterni B, Castaigne S, Guilhot F, Dombret H, Vey N; Acute Leukemia French Association.; Groupe Ouest-Est des leucémies et autres maladies du sang (GOELAMS).; Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup..

J Clin Oncol. 2009 Oct 1;27(28):4747-53. doi: 10.1200/JCO.2008.21.0674.

PMID:
19720919
10.

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE.

Biol Blood Marrow Transplant. 2002;8(8):435-43.

PMID:
12234169
11.

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

Schaich M, Schlenk RF, Al-Ali HK, Döhner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G.

Haematologica. 2007 Jun;92(6):763-70.

12.

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H, Heil G.

J Clin Oncol. 2004 Sep 15;22(18):3741-50.

PMID:
15289486
13.

[Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation].

Shi HX, Jiang B, Qiu JY, Lu XJ, Fu JF, Wang DB, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2005 Aug;26(8):481-4. Chinese.

PMID:
16383240
14.

Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).

Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD.

Blood. 1997 Aug 15;90(4):1643-8.

15.

Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.

Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fière D, Leverger G, Dombret H, Baruchel A.

J Clin Oncol. 2003 Mar 1;21(5):774-80.

PMID:
12610173
16.

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K; AML Study Group Ulm. Acute myeloid leukemia..

Blood. 2002 Dec 15;100(13):4372-80.

17.

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.

18.

Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience.

Lee KW, Choi IS, Roh EY, Kim DY, Yun T, Lee DS, Yoon SS, Park S, Kim BK, Kim NK.

Ann Hematol. 2004 Apr;83(4):218-24.

PMID:
14628154
19.

Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.

Blum W, Mrózek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, Bloomfield CD.

Cancer. 2004 Sep 15;101(6):1420-7. Review.

20.

Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.

Junghanss C, Waak M, Knopp A, Kleine HD, Kundt G, Leithäuser M, Hilgendorf I, Wolff D, Casper J, Freund M.

Neoplasma. 2005;52(5):402-10.

PMID:
16151585

Supplemental Content

Support Center